|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-5-27
|
|
pubmed:abstractText |
It has been proposed that hormonal supplementation during prolonged GnRH agonist therapy prevents hypoestrogenic side effects, including bone loss. The optimal combination for long-term treatments with safe metabolic profile remains questionable. A norprogesterone derivative, promegestone, was assessed for the first time in a double-blind trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0268-1161
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1465-71
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15105403-Absorptiometry, Photon,
pubmed-meshheading:15105403-Adult,
pubmed-meshheading:15105403-Bone Density,
pubmed-meshheading:15105403-Double-Blind Method,
pubmed-meshheading:15105403-Drug Administration Schedule,
pubmed-meshheading:15105403-Drug Therapy, Combination,
pubmed-meshheading:15105403-Endometriosis,
pubmed-meshheading:15105403-Estradiol,
pubmed-meshheading:15105403-Female,
pubmed-meshheading:15105403-Humans,
pubmed-meshheading:15105403-Leuprolide,
pubmed-meshheading:15105403-Lumbar Vertebrae,
pubmed-meshheading:15105403-Promegestone,
pubmed-meshheading:15105403-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial.
|
|
pubmed:affiliation |
Service de Gynécologie-Obstétrique, Hôpital Antoine Béclère, AP-HP, 92141 Clamart, Paris, France. herve.fernandez@abc.ap-hop-paris.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
